Ivosidenib
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
- Ivosidenib
- Ivosidenib: From IDH1-Mutant AML (External Reference) to Bulbar Polio — A Low-Confidence TxGNN Signal
Ivosidenib: From IDH1-Mutant AML (External Reference) to Bulbar Polio — A Low-Confidence TxGNN Signal
One-Sentence Summary
Ivosidenib (DB14568) has no original-indication or Finnish licensing record in this evidence pack; based on external background knowledge it is a targeted inhibitor of mutant IDH1, used in IDH1-mutant acute myeloid leukemia (AML) — this is not sourced from the dataset itself. The TxGNN model's top-ranked prediction, Bulbar Polio, has 0 clinical trials and 0 publications, and the rationale field explicitly flags it as having no plausible mechanistic link — most likely model noise. Two lower-ranked but mechanistically more coherent signals — treatment-related AML/MDS (alkylating-agent- and radiation-related) — remain at "Research Question" status pending dedicated evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on file (no original_indications, no Finnish licenses); externally known as IDH1-mutant AML |
| Predicted New Indication | Bulbar Polio (rank 1) |
| TxGNN Prediction Score | 99.31% |
| Evidence Level | L5 (model prediction only, no studies) |
| Finland Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in this evidence pack (original_moa: [Data Gap]). Based on externally known information, ivosidenib is a targeted small-molecule inhibitor of mutant IDH1, an enzyme implicated in AML — this is background context, not data drawn from the dataset.
For the top-ranked prediction, bulbar polio, the rationale field in the evidence pack itself states there is no identifiable mechanistic connection: bulbar polio is an acute neurological disease caused by poliovirus infection of brainstem motor neurons, with no known pathological relationship to IDH1 metabolic-enzyme inhibition. With zero clinical trials, zero literature, and no mechanistic rationale, this signal is best interpreted as model noise or an atypical association rather than a genuine repurposing hypothesis.
By contrast, the two lower-ranked predictions — treatment-related AML/MDS following alkylating agents or radiation therapy — are mechanistically more coherent: both are recognized subtypes of the broader AML/MDS disease category, and a subset of cases can carry IDH1 R132 mutations, which would overlap with ivosidenib's known mechanism. However, the evidence pack contains no subtype-specific trials, literature, or IDH1-mutation-prevalence data for these subtypes, so this remains an indirect, unconfirmed inference (see below).
Additional Predicted Indications (Lower Rank, Higher Mechanistic Plausibility)
| Rank | Disease | TxGNN Score | Evidence Level | Decision Stage | Recommendation |
|---|---|---|---|---|---|
| 2 | AML/MDS related to alkylating agent | 99.26% | L4 | S1 | Research Question |
| 3 | AML/MDS related to radiation | 99.26% | L4 | S1 | Research Question |
Both are treatment-related AML/MDS subtypes with a plausible (though unconfirmed) overlap with ivosidenib's known IDH1-mutant AML mechanism. No clinical trials or literature specific to these subtypes were found in the queried sources (ClinicalTrials.gov, ICTRP, PubMed — all returned 0 results).
Clinical Trial Evidence
Currently no related clinical trials registered for any of the three TxGNN-predicted indications (bulbar polio; treatment-related AML/MDS – alkylating agent; treatment-related AML/MDS – radiation).
Literature Evidence
Currently no related literature available for any of the three TxGNN-predicted indications.
Finland Market Information
Ivosidenib is currently not marketed in Finland. No marketing authorizations are on file (0 licenses).
Cytotoxicity
Ivosidenib's predicted and externally known indications are oncologic/hematologic (AML/MDS), so this section is included for completeness. Classification below is based on the drug's known identity as an IDH1 inhibitor (external reference); specific toxicity data are not present in this evidence pack.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (mutant IDH1 enzyme inhibitor), not a conventional cytotoxic agent |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked TxGNN prediction (bulbar polio) has no supporting clinical trials, no literature, and no plausible mechanistic link — the evidence pack's own rationale identifies it as likely model noise. The two mechanistically more plausible predictions (treatment-related AML/MDS) remain at an early "Research Question" stage with no dedicated supporting evidence.
To proceed, the following is needed:
- TFDA package insert / warnings and contraindications data (blocking gap, DG001)
- Confirmed mechanism-of-action data via DrugBank API (DG002)
- If pursuing the treatment-related AML/MDS signals: subtype-specific IDH1 mutation prevalence data and dedicated clinical trial or case-series evidence
- DDI data source resolution (current query returned "not found")
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.